UGN-102 not checked

UroGen Pharma Ltd.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
1 active
4 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.”In the company’s words, NCT05243550 on ClinicalTrials.gov
Tested for
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Main trialPhase 3
“This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).”In the company’s words, NCT05243550 on ClinicalTrials.gov

Other drugs for Bladder Cancer

All 85 drugs for Bladder Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 26 Apr 2023 A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Phase 3Completed 2 Feb 2023 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
Phase 3Terminated 17 Mar 2023 A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Phase 2Completed 3 Jan 2020 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow UGN-102

Following is part of Solo: you see every change to UGN-102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in